{"id":"e7090","safety":{"commonSideEffects":[{"rate":"null","effect":"Increased risk of diabetic ketoacidosis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting SGLT2, E7090 reduces glucose reabsorption in the kidneys, leading to increased glucose excretion in the urine and decreased glucose levels in the blood. This mechanism is thought to contribute to its therapeutic effects in treating diabetes.","oneSentence":"E7090 is a selective and potent inhibitor of the sodium-glucose cotransporter 2 (SGLT2).","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:36:13.442Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT04572295","phase":"PHASE1","title":"A Study of E7090 as Monotherapy and in Combination With Other Anticancer Agents in Participants With Estrogen Receptor Positive (ER+) and Human Epidermal Growth Receptor 2 Negative (HER2-) Recurrent/Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eisai Co., Ltd.","startDate":"2020-10-09","conditions":"Breast Neoplasms","enrollment":51},{"nctId":"NCT04238715","phase":"PHASE2","title":"A Study of E7090 in Participants With Unresectable Advanced or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor (FGFR) 2 Gene Fusion","status":"COMPLETED","sponsor":"Eisai Co., Ltd.","startDate":"2020-01-22","conditions":"Cholangiocarcinoma","enrollment":63},{"nctId":"NCT04271488","phase":"PHASE1","title":"Study to Evaluate the Pharmacokinetics (PK) of E7090 (Herein Referred to as Tasurgratinib) and Its Metabolite in Participants With Mild and Moderate Hepatic Impairment Compared to Healthy Participants","status":"RECRUITING","sponsor":"Eisai Co., Ltd.","startDate":"2020-02-27","conditions":"Hepatic Impairment","enrollment":18},{"nctId":"NCT02275910","phase":"PHASE1","title":"Phase 1 Study of E7090 in Subjects With Solid Tumor","status":"COMPLETED","sponsor":"Eisai Co., Ltd.","startDate":"2014-10-28","conditions":"Tumors","enrollment":40},{"nctId":"NCT04962867","phase":"PHASE2","title":"NCCH2006/MK010 Trial (FORTUNE Trial)","status":"RECRUITING","sponsor":"National Cancer Center, Japan","startDate":"2021-06-15","conditions":"Advanced or Recurrent Solid Tumors, FGFR Gene Alterations","enrollment":75},{"nctId":"NCT04565574","phase":"PHASE1","title":"A Study to Assess the Effect of Food Intake and Drug-drug Interactions of E7090 When Co-administered With Rabeprazole or Rifampin in Healthy Participants","status":"COMPLETED","sponsor":"Eisai Co., Ltd.","startDate":"2020-10-16","conditions":"Healthy Participants","enrollment":42},{"nctId":"NCT04493255","phase":"PHASE1","title":"A Study to Determine the Metabolism and Elimination of [14C]E7090 in Healthy Male Participants","status":"COMPLETED","sponsor":"Eisai Limited","startDate":"2020-09-09","conditions":"Healthy Volunteers","enrollment":8}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":9,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"E7090","genericName":"E7090","companyName":"Eisai Co., Ltd.","companyId":"eisai-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"E7090 is a selective and potent inhibitor of the sodium-glucose cotransporter 2 (SGLT2). Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":5,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}